News
GOSS
10.98
+0.09%
0.01
Gossamer Bio Files Prospectus Related To The Proposed Resale Or Other Disposition By The Selling Securityholders Of Up To 1,697,363 Shares Of Common Stock
Benzinga · 15h ago
Gossamer Bio registers to sell 1.7M shares of common stock for holders
TipRanks · 15h ago
Weekly Report: what happened at GOSS last week (1109-1113)?
Weekly Report · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Conmed (CNMD) and Gossamer Bio (GOSS)
TipRanks · 3d ago
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS)
TipRanks · 5d ago
Gossamer Bio is Chardan's top small-cap pick for 2027
Seeking Alpha · 5d ago
Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results
Benzinga · 5d ago
Gossamer Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
Gossamer Bio Price Target Cut to $96.00/Share From $120.00 by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96
Benzinga · 5d ago
Gossamer Bio Is Maintained at Neutral by Wedbush
Dow Jones · 5d ago
Gossamer Bio Price Target Cut to $32.00/Share From $80.00 by Wedbush
Dow Jones · 5d ago
Wedbush Maintains Neutral on Gossamer Bio, Lowers Price Target to $32
Benzinga · 5d ago
Gossamer Bio price target lowered to $96 from $120 at Piper Sandler
TipRanks · 5d ago
Press Release: Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 6d ago
Press Release: Gossamer Bio Announces Third -2-
Dow Jones · 6d ago
Gossamer Bio reports Q3 EPS ($7.36), consensus ($3.93)
TipRanks · 6d ago
Gossamer Bio: Q3 Earnings Snapshot
Barchart · 6d ago
TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates
NASDAQ · 11/09 12:25
Weekly Report: what happened at GOSS last week (1102-1106)?
Weekly Report · 11/09 10:14
More
Webull provides a variety of real-time GOSS stock news. You can receive the latest news about Gossamer Bio through multiple platforms. This information may help you make smarter investment decisions.
About GOSS
Gossamer Bio, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The Company's lead product candidate is Seralutinib (GB002), is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR. Seralutinib is designed to inhibit multiple kinases in the pathology of PAH. The PDGFR is a tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. The c-KIT pathway was also identified as a factor involved in pulmonary vascular remodeling, particularly in the cells implicated in perivascular inflammation.